This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOPatient ProfileOrder ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorEventsMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
Every breath they take matters
Discuss vaccination today. Don't wait
ABRYSVO®: CDC-recommended as a single dose for all adults aged 75 and older and for adults 60-74 years who are at increased risk of severe disease1,2†
ABRYSVO®: CDC-recommended as a single dose for all adults aged 75 and older and for adults 60-74 years who are at increased risk of severe disease1,2†
View the Clinical Data Loading ReferencesRisk conditions associated with increased risk include: chronic cardiovascular disease, chronic lung or respiratory disease, end-stage renal disease or dependence on dialysis or other renal replacement therapy, diabetes complicated by CKD or other end-organ damage or requiring insulin/SGLT2 inhibitor, neurologic or neuromuscular condition which makes it difficult to breathe, chronic liver disease, chronic hematologic condition, severe obesity (body mass index ≥40 kg/m2), moderate or severe immune compromise, residence in a nursing home, or any other conditions that a healthcare provider determines increases risk of severe disease due to respiratory infection.2RSV vaccination should be given only to adults who have not yet received a dose of RSV vaccine. RSV vaccination will have the most benefit if given late summer or early fall. However, providers can give it year round.2 Estimated based on average respiratory rates from birth to age 60.3-5 Powerful protection against RSV in older adults§

86% vaccine efficacy against RSV-LRTD with ≥3 symptoms (96.66% CI: 32.0, 98.7)6

67% vaccine efficacy against RSV-LRTD with ≥2 symptoms (96.66% CI: 28.8, 85.8)6

 View Efficacy Data Additional Data

§Interim data from season 1. The median duration of efficacy follow-up was 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.6

 Rates of systemic AEs similar to placebo in older adults Similar rates of systemic AEs observed between ABRYSVO and placebo groups6

The most common solicited local and systemic adverse reactions (≥10%) were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%).6 View Safety Data Loading
Take every opportunity to vaccinate this RSV season1,2
Adults 60-74 with certain medical conditions are at increased risk of severe RSV2
These include Vaccinate your eligible patients aged 60 years and older today with ABRYSVO6 Vaccine Locator Tool LoadingApproved for 2 Vulnerable Populations

The only RSV vaccine approved for both adults aged 60+ and pregnant individuals (at 32-36 weeks of gestation) for the protection of infants (from birth through 6 months) via maternal immunization6

Learn more about the maternal indication

LoadingABRYSVO Reconstitution

See Pfizer's convenient, needle-free|| reconstitution kit6

||Needle required for intramuscular injection is not included.

LoadingResources and Access Info

Get the support you need and learn more about costs and coverage

LoadingReferencesAE=adverse event; BMI=body mass index; CDC=Centers for Disease Control and Prevention; CKD=chronic kidney disease; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; SGLT2=sodium glucose cotransporter-2.
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

 View ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
References:Centers for Disease Control and Prevention (CDC). CDC updates RSV vaccination recommendation for adults. Published June 26, 2024. Accessed July 3, 2024. https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html Melgar M, Britton A. ACIP adult RSV work group clinical considerations. Centers for Disease Control and Prevention (CDC). Published June 26, 2024. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/12-RSV-Adult-Melgar-508.pdfJohns Hopkins Medicine. Vital signs (body temperature, pulse rate, respiration rate, blood pressure). Accessed August 22, 2023. https://www.hopkinsmedicine.org/health/conditions-and-diseases/vital-signs-body-temperature-pulse-rate-respiration-rate-blood-pressureUpToDate. Normal respiratory rate and heart rate in children. Accessed August 12, 2023. https://www.uptodate.com/contents/the-pediatric-physical-examination-general-principles-and-standard-measurements#H10Data on file. Pfizer Inc.ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-A1G-USA-1357
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with older adults, the most commonly reported (≥10%) adverse reactions were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367